Targeting patients for anticoagulant prophylaxis trials in patients with cancer: Who is at highest risk?

Trousseau, 1865, Phlegmasia alba dolens, Clinique Medicale de l'Hotel-Dieu de Paris, 3 Bouillaud, 1823, Obliteratioin des veines et de son influence sur la formation des hydropisies particelles: considedration sur la hydropiesies passive et general, Arch Gen Med, 1, 188 Blom, 2006, Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study, J Thromb Haemost, 4, 529, 10.1111/j.1538-7836.2006.01804.x Hansson, 1997, Deep vein thrombosis and pulmonary embolism in the general population. ‘The Study of Men Born in 1913’, Arch Intern Med, 157, 1665, 10.1001/archinte.157.15.1665 Heit, 2005, Cancer and venous thromboembolism: scope of the problem, Cancer Control, 12, 5, 10.1177/1073274805012003S02 Prandoni, 2005, Cancer and venous thromboembolism, Lancet Oncol, 6, 401, 10.1016/S1470-2045(05)70207-2 Rickles, 2001, Epidemiology of thrombosis in cancer, Acta Haematol, 106, 6, 10.1159/000046583 Sorensen, 2000, Prognosis of cancers associated with venous thromboembolism, N Engl J Med, 343, 1846, 10.1056/NEJM200012213432504 Green, 1992, Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin, Lancet, 339, 1476, 10.1016/0140-6736(92)92064-M Gould, 1999, Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials, Ann Intern Med, 130, 800, 10.7326/0003-4819-130-10-199905180-00003 Hettiarachchi, 1999, Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread, Thromb Haemost, 82, 947, 10.1055/s-0037-1615937 Siragusa, 1996, Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis, Am J Med, 100, 269, 10.1016/S0002-9343(97)89484-3 Kakkar, 2004, Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS), J Clin Oncol, 22, 1944, 10.1200/JCO.2004.10.002 Klerk, 2005, The effect of low molecular weight heparin on survival in patients with advanced malignancy, J Clin Oncol, 23, 2130, 10.1200/JCO.2005.03.134 Lee, 2005, Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism, J Clin Oncol, 23, 2123, 10.1200/JCO.2005.03.133 Levitan, 1999, Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data, Medicine (Baltimore), 78, 285, 10.1097/00005792-199909000-00001 Stein, 2006, Incidence of venous thromboembolism in patients hospitalized with cancer, Am J Med, 119, 60, 10.1016/j.amjmed.2005.06.058 Kwong SL, Perkins CL, Morris CR, Allen M, Wright WE. Cancer In California: 1988 1999. Sacramento: Department of Health Services, Cancer Surveillance Section; 2001 December, 2001. White, 2000, Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty, N Engl J Med, 343, 1758, 10.1056/NEJM200012143432403 Romano, 1995, The California Hospital Outcomes Project: using administrative data to compare hospital performance, The Joint Commission journal on quality improvement, 21, 668, 10.1016/S1070-3241(16)30195-X Chew, 2006, Incidence of venous thromboembolism and its effect on survival among patients with common cancers, Arch Intern Med, 166, 458, 10.1001/.458 Alcalay, 2006, Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival, J Clin Oncol, 24, 1112, 10.1200/JCO.2005.04.2150 Semrad, 2007, Epidemiology of venous thromboembolism in 9489 patients with malignant glioma, J Neurosurg, 106, 601, 10.3171/jns.2007.106.4.601 Rodriguez, 2007, Venous thromboembolism in ovarian cancer, Gynecologic oncology, 105, 784, 10.1016/j.ygyno.2007.02.024 White, 2005, Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996, Thromb Haemost, 93, 298, 10.1160/TH04-08-0506 Heit, 2002, Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study, Arch Intern Med, 162, 1245, 10.1001/archinte.162.11.1245 Chew, 2007, Incidence of venous thromboembolism and the impact on survival in breast cancer patients, J Clin Oncol, 25, 70, 10.1200/JCO.2006.07.4393 White, 2003, Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures, Thromb Haemost, 90, 446 Prandoni, 1999, Cancer and venous thromboembolism: an overview, Haematologica, 84, 437 Egermayer, 1999, Survey of the use of thromboprophylaxis for medical patients at Christchurch Hospital, N Z Med J, 112, 246 Piccirillo, 2004, Prognostic importance of comorbidity in a hospital-based cancer registry, JAMA, 291, 2441, 10.1001/jama.291.20.2441 Comorbidity Elixhauser, 1998, Comorbidity measures for use with administrative data, Med Care, 36, 8, 10.1097/00005650-199801000-00004 Khorana, 2005, Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study, Cancer, 104, 2822, 10.1002/cncr.21496 Otten, 2004, Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon, Arch Intern Med, 164, 190, 10.1001/archinte.164.2.190 Haddad, 2006, Chemotherapy-induced thrombosis, Thromb Res, 118, 555, 10.1016/j.thromres.2005.10.015 Khorana AA, Kuderer NM, Culakova GH, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. ISTH, 2007, Geneva Switzerland. Abstract. Zwicker J, Kos C, Johnston K, HA. L, Furie B, Furie B. Cancer-Associated Thrombosis: Tissue Factor-Bearing Microparticles Are Associated With An Increased Risk Of Venous Thromboembolic Events In Cancer Patients. ISTH, 2007, Geneva Switzerland. Abstract. Altinbas, 2004, A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer, J Thromb Haemost, 2, 1266, 10.1111/j.1538-7836.2004.00871.x Maraveyas A, Holmes M, Lofts F, Wedgewood K, Gardiner E, Sgouros J. Chemoanticoagulation Versus Chemotherapy In Advanced Pancreatic Cancer (APC): Results of the Interim Analysis of the Fragem Trial. 2007, ISTH, Geneva Switzerland. Abstract. Kakkar, 2005, Low-molecular-weight heparin and survival in patients with malignant disease, Cancer Control, 12, 22, 10.1177/1073274805012003S05